Journal of Inherited Metabolic Disease

, Volume 35, Issue 6, pp 1071–1079 | Cite as

Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series

  • Anke Thümler
  • Elke Miebach
  • Christina Lampe
  • Susanne Pitz
  • Wolfgang Kamin
  • Christoph Kampmann
  • Bianca Link
  • Eugen Mengel
Original Article



To assess clinical features and general health status of adult patients with mucopolysaccharidosis (MPS) VI.


This report includes the clinical history of patients older than 18 years with slowly progressing MPS VI and the retrospective analysis of the outcomes of available data collected between September 2003 and October 2008 at the Center of Pediatric and Adolescent Medicine, University Medical Center, Johannes Gutenberg-University of Mainz, Germany. Variables included were urinary glycosaminoglycan (uGAG) level, mutation analysis, body height, forced vital capacity (FVC), 6-minute walk test, echocardiographic findings, the need for craniocervical decompression surgery, orthopaedic findings and ophthalmological assessments.


The analysis included nine patients with MPS VI aged 19-29 years. The median age at diagnosis was 12 (range 6–20) years. At the time of the assessment (median age 25 years), median uGAG was 29 (range 15-149) μg/mg creatinine and median height 152 (range 136–161) cm. All patients had a FVC below standard values, seven showed reduced endurance in the 6-minute-walk test, all had valve changes with valve replacement in three, two underwent craniocervical decompression surgery, two underwent carpal tunnel surgery, five had ear/nose/throat (ENT) interventions, seven had hip pain/dysplasia, seven had corneal clouding and two were visually impaired.


Although patients with slowly progressing MPS VI are a heterogeneous group showing disease manifestations in several organs, they seem to have some typical characteristics in common. Despite the attenuated clinical course, many of these patients show severe morbidity. Therefore, early diagnosis and proper follow-up and treatment are essential.



The authors are grateful to Ismar Healthcare NV for their assistance in writing of the manuscript, which was funded by BioMarin Europe Ltd.

Competing interests

Dr. Elke Miebach has received travel expenses and speakers fees for scientific meetings by BioMarin Pharmaceutical Inc., Genzyme Corp. and Shire, Inc., Dr. Christina Lampe has received travel expenses and speakers fees for scientific meetings by BioMarin, Shire Inc. and Genzyme. Prof. Susanne Pitz has received travel and research grants from BioMarin, Genzyme and Shire, Inc., Dr. Wolfgang Kamin and Dr. Christoph Kampmann have received travel and research grants as well as speakers fees for scientific meetings by BioMarin, Genzyme and Shire Inc., Dr. Bianca Link has received travel and research grants as well as honoraria for scientific presentations from BioMarin, Genzyme and Shire Inc. Dr. Eugen Mengel received speakers fee and research grants from Genzyme and Shire, he acts as consultant for BioMarin respective MPS IV. Dr. Anke Thümler has no conflict of interest.


The preparation of this manuscript was supported by BioMarin Europe Ltd.


  1. Ashworth JL, Biswas S, Wraith E, Lloyd IC (2006) The ocular features of the mucopolysaccharidoses. Eye 20:553–563PubMedCrossRefGoogle Scholar
  2. Azevedo ACMM, Schwartz IV, Kalakun L et al (2004) Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 66:208–213PubMedCrossRefGoogle Scholar
  3. Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRefGoogle Scholar
  4. Decker C, Yu Z, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3:89–100PubMedGoogle Scholar
  5. Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387PubMedGoogle Scholar
  6. Fesslová V, Corti P, Sersale G et al (2009) The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 19:170–178PubMedCrossRefGoogle Scholar
  7. Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120:405–418PubMedCrossRefGoogle Scholar
  8. Gottwald I, Hughes J, Stewart F et al (2011) Attenuated mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) due to homozygosity for the p.Y210C mutation in the ARSB gene. Mol Genet Metab 103:300–302PubMedCrossRefGoogle Scholar
  9. Harmatz P, Whitley CB, Waber L et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144:574–580PubMedCrossRefGoogle Scholar
  10. Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115:e681–e689PubMedCrossRefGoogle Scholar
  11. Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533–539PubMedCrossRefGoogle Scholar
  12. Harmatz P, Yu ZF, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis 33:51–60PubMedCrossRefGoogle Scholar
  13. Hendriksz CJ, Giugliani R, Harmatz P et al (2011) Design, baseline characteristics and early findings of the MPS VI Clinical Surveillance Program (CSP). J Inherit Metab Dis. doi: 10.1007/s10545-011-9410-9
  14. Isbrandt D, Arlt G, Brooks DA, Hopwood JJ, von Figura K, Peters C (1994) Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes. Am J Hum Genet 54:454–463PubMedGoogle Scholar
  15. Karageorgos L, Brooks DA, Pollard A et al (2007) Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 28:897–903PubMedCrossRefGoogle Scholar
  16. Leal GN, de Paula AC, Leone C, Kim CA (2010) Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 20:254–261PubMedCrossRefGoogle Scholar
  17. Litjens T, Brooks DA, Peters C, Gibson GJ, Hopwood JJ (1996) Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients. Am J Hum Genet 58:1127–1134PubMedGoogle Scholar
  18. McGill JJ, Inwood AC, Coman DJ, Lipke ML et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age–a sibling control study. Clin Genet 77:492–498PubMedCrossRefGoogle Scholar
  19. Mut M, Cila A, Varli K, Akalan N (2005) Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature. Clin Neurol Neurosurg 107:230–235PubMedCrossRefGoogle Scholar
  20. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3421–3452Google Scholar
  21. Scarpa M, Buffone E, La Marca P, Campello M, Rampazzo A (2010) Difficulties in diagnosing slowly progressive mucopolysaccharidosis VI: a case series. J Pediatr Rehabil Med 3:71–75PubMedGoogle Scholar
  22. Swiedler SJ, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet 134A:144–150PubMedCrossRefGoogle Scholar
  23. Thorne JA, Javadpour M, Hughes DG, Wraith E, Cowie RA (2001) Craniovertebral abnormalities in type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 48:849–853PubMedGoogle Scholar
  24. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S (2010) Mucopolysaccharidosis VI. Orphanet J Rare Dis 5:5PubMedCrossRefGoogle Scholar
  25. Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jüngst BK (1995) Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 154:98–101PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2012

Authors and Affiliations

  • Anke Thümler
    • 1
  • Elke Miebach
    • 2
  • Christina Lampe
    • 2
  • Susanne Pitz
    • 3
  • Wolfgang Kamin
    • 4
  • Christoph Kampmann
    • 5
  • Bianca Link
    • 6
  • Eugen Mengel
    • 2
    • 7
  1. 1.Department of PsychiatryUniversity of MainzMainzGermany
  2. 2.Villa Metabolica, Center of Pediatric and Adolescent MedicineUniversity Medical Center, Johannes Gutenberg-University of MainzMainzGermany
  3. 3.Department of OphthalmologyUniversity Medical Center, Johannes Gutenberg-University of MainzMainzGermany
  4. 4.Children’s Hospital Evangelisches Krankenhaus HammHammGermany
  5. 5.Department of Cardiology, Center of Pediatric and Adolescent MedicineUniversity Medical Center, Johannes Gutenberg-University of MainzMainzGermany
  6. 6.Division of Metabolism, Connective Tissue UnitUniversity Children’s HospitalZurichSwitzerland
  7. 7.Department of PediatricsMainzGermany

Personalised recommendations